FLASH放疗治疗胸部症状性骨转移(FAST-02):一种新型放疗方法的前瞻性研究方案
FAST-02是一项单臂临床试验,计划纳入10例胸部1-3处疼痛性骨转移(除外脊柱)患者,采用质子FLASH系统以≥40 Gy/s单次8 Gy治疗,主要终点为疼痛缓解与安全性,同时评估临床工作流程可行性。
要点
- 质子FLASH以≥40 Gy/s单次8 Gy治疗胸部疼痛性骨转移,除外脊柱转移。
- 主要终点为疼痛缓解与安全性,并评估设备问题及治疗床时间等工作流程指标。
- 疼痛问卷治疗后连续10天完成,疼痛反应与不良事件随访至12个月及之后每6个月。
核心结论
- 该前瞻性临床试验将为评估质子FLASH姑息治疗胸部骨转移的疗效与安全性提供临床数据。
- 阳性结果将支持进一步探索FLASH放疗用于其他临床适应症,包括接受根治性治疗的患者人群。
研究设计与样本
- 单臂临床试验,在FDA研究性器械豁免(IDE)下开展,批准纳入10例胸部1-3处疼痛性骨转移患者,排除脊柱骨转移。
- 治疗为单次8 Gy,在FLASH质子治疗系统上以≥40 Gy/s给予单束传输质子束。
- 主要研究终点为疗效(疼痛缓解)和安全性。
- 治疗后连续10天完成治疗部位疼痛爆发的患者问卷。
- 疼痛反应和不良事件在治疗当天及第7天、第15天、第1、2、3、6、9、12个月评估,此后每6个月评估。
主要发现
- FAST-01首次人体临床试验已证明质子FLASH治疗四肢骨转移的临床可行性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: FLASH therapy is a treatment technique in which radiation is delivered at ultra-high dose rates (≥ 40 Gy/s). The first-in-human FAST-01 clinical trial demonstrated the clinical feasibility of proton FLASH in the treatment of extremity bone metastases. The objectives of this investigation are to assess the toxicities of treatment and pain relief in study participants with painful thoracic bone metastases treated with FLASH radiotherapy, as well as workflow metrics in a clinical setting. METHODS: This single-arm clinical trial is being conducted under an FDA investigational device exemption (IDE) approved for 10 patients with 1-3 painful bone metastases in the thorax, excluding bone metastases in the spine. Treatment will be 8 Gy in a single fraction administered at ≥ 40 Gy/s on a FLASH-enabled proton therapy system delivering a single transmission proton beam. Primary study endpoints are efficacy (pain relief) and safety. Patient questionnaires evaluating pain flare at the treatment site will be completed for 10 consecutive days post-RT. Pain response and adverse events (AEs) will be evaluated on the day of treatment and on day 7, day 15, months 1, 2, 3, 6, 9, and 12, and every 6 months thereafter. The outcomes for clinical workflow feasibility are the occurrence of any device issues as well as time on the treatment table. DISCUSSION: This prospective clinical trial will provide clinical data for evaluating the efficacy and safety of proton FLASH for palliation of bony metastases in the thorax. Positive findings will support the further exploration of FLASH radiation for other clinical indications including patient populations treated with curative intent. REGISTRATION: ClinicalTrials.gov NCT05524064.
引用
- Daugherty EC, Zhang Y, Xiao Z, et al. FLASH radiotherapy for the treatment of symptomatic bone metastases in the thorax (FAST-02): protocol for a prospective study of a novel radiotherapy approach. Radiat Oncol. 2024. PMID: 38475815. doi:10.1186/s13014-024-02419-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。